Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Nektar Therapeutics (NKTR) has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, scheduled for May 20, 2025, at the Nasdaq Headquarters in New York City. The company will host a fireside chat that will be webcast starting at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. The presentation will be accessible through a webcast link and on Nektar's investor relations website, with a replay available for 30 days. Interested parties seeking one-on-one meetings with management should contact their H.C. Wainwright representative.
Nektar Therapeutics (NKTR) ha annunciato la sua partecipazione al 3掳 Annuale BioConnect Investor Conference di H.C. Wainwright, previsto per il 20 maggio 2025, presso la sede del Nasdaq a New York City. L'azienda terr脿 una chiacchierata informale trasmessa in webcast a partire dalle 13:30 ora Eastern / 10:30 ora Pacific. La presentazione sar脿 disponibile tramite un link webcast e sul sito web delle relazioni con gli investitori di Nektar, con una replica accessibile per 30 giorni. Chi fosse interessato a incontri individuali con il management 猫 invitato a contattare il proprio rappresentante H.C. Wainwright.
Nektar Therapeutics (NKTR) ha anunciado su participaci贸n en la 3陋 Conferencia Anual BioConnect para Inversores de H.C. Wainwright, programada para el 20 de mayo de 2025, en la sede de Nasdaq en Nueva York. La compa帽铆a realizar谩 una charla informal que ser谩 transmitida por webcast a partir de las 1:30 p.m. hora del Este / 10:30 a.m. hora del Pac铆fico. La presentaci贸n estar谩 disponible a trav茅s de un enlace de webcast y en el sitio web de relaciones con inversores de Nektar, con una repetici贸n disponible durante 30 d铆as. Las personas interesadas en reuniones individuales con la direcci贸n deben contactar a su representante de H.C. Wainwright.
Nektar Therapeutics (NKTR)电� 2025雲� 5鞗� 20鞚� 雺挫殨 雮橃姢雼� 氤胳偓鞐愳劀 鞓堨爼霅� H.C. Wainwright 鞝�3須� 鞐半 BioConnect 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓电� 霃欕秬 鞁滉皠 鞓ろ泟 1鞁� 30攵� / 韮滍弶鞏� 鞁滉皠 鞓れ爠 10鞁� 30攵�攵�韯� 鞗轨簮鞀ろ姼搿� 歆勴枆霅樀鐢 牍勱车鞁� 雽�頇旊ゼ 欤检禍頃� 鞓堨爼鞛呺媹雼�. 氚滍憸电� 鞗轨簮鞀ろ姼 毵來伂鞕� Nektar 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞝戩啀頃� 靾� 鞛堨溂氅�, 30鞚� 霃欖晥 鞛嫓觳澊 臧�電ロ暕雼堧嫟. 瓴届榿歆勱臣鞚� 鞚茧寑鞚� 氙疙寘鞚� 鞗愴晿电� 攵勲摛鞚� H.C. Wainwright 雼措嫻鞛愳棎瓴� 鞐半澖頃橃嫓旮� 氚旊瀺雼堧嫟.
Nektar Therapeutics (NKTR) a annonc茅 sa participation 脿 la 3e conf茅rence annuelle BioConnect pour investisseurs d'H.C. Wainwright, pr茅vue le 20 mai 2025 au si猫ge du Nasdaq 脿 New York. La soci茅t茅 animera une discussion informelle diffus茅e en webcast 脿 partir de 13h30 heure de l'Est / 10h30 heure du Pacifique. La pr茅sentation sera accessible via un lien webcast et sur le site des relations investisseurs de Nektar, avec une rediffusion disponible pendant 30 jours. Les personnes souhaitant organiser des r茅unions individuelles avec la direction sont invit茅es 脿 contacter leur repr茅sentant H.C. Wainwright.
Nektar Therapeutics (NKTR) hat seine Teilnahme an der 3. j盲hrlichen BioConnect Investorenkonferenz von H.C. Wainwright angek眉ndigt, die am 20. Mai 2025 im Nasdaq-Hauptquartier in New York City stattfinden wird. Das Unternehmen wird ein informelles Gespr盲ch veranstalten, das ab 13:30 Uhr Eastern Time / 10:30 Uhr Pacific Time per Webcast 眉bertragen wird. Die Pr盲sentation ist 眉ber einen Webcast-Link und auf der Investor-Relations-Website von Nektar zug盲nglich, mit einer Wiederholung, die f眉r 30 Tage verf眉gbar ist. Interessenten, die Einzelgespr盲che mit dem Management w眉nschen, sollten ihren H.C. Wainwright-Ansprechpartner kontaktieren.
- None.
- None.
- H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025 鈥� webcast to be available at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time 鈥� link聽
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website:聽https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
Contact:
For Investors:
Ahu Demir, Ph.D.
LifeSci Advisors, LLC
[email protected]
212-915-3820
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
[email protected]
View original content to download multimedia:
SOURCE Nektar Therapeutics
FAQ
When is Nektar Therapeutics (NKTR) presenting at the H.C. Wainwright BioConnect Conference 2025?
Where can I watch Nektar Therapeutics' (NKTR) H.C. Wainwright conference presentation?
How can investors arrange meetings with Nektar Therapeutics (NKTR) management at the conference?
Where is the H.C. Wainwright BioConnect Conference 2025 being held?
